NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.
CASRN: 914088-09-8
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of brentuximab during breastfeeding. Because brentuximab is a large protein molecule with a molecular weight of about 153,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, brentuximab vedotin should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during brentuximab therapy.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Brentuximab Vedotin
CAS Registry Number
914088-09-8
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Cetuximab[Drugs and Lactation Database (...]Review Cetuximab. Drugs and Lactation Database (LactMed). 2006
- Review Siltuximab[Drugs and Lactation Database (...]Review Siltuximab. Drugs and Lactation Database (LactMed). 2006
- Review Basiliximab[Drugs and Lactation Database (...]Review Basiliximab. Drugs and Lactation Database (LactMed). 2006
- Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.[Ther Adv Hematol. 2012]Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Vaklavas C, Forero-Torres A. Ther Adv Hematol. 2012 Aug; 3(4):209-25.
- Review Pertuzumab[Drugs and Lactation Database (...]Review Pertuzumab. Drugs and Lactation Database (LactMed). 2006
- Brentuximab Vedotin - Drugs and Lactation Database (LactMed)Brentuximab Vedotin - Drugs and Lactation Database (LactMed)
Your browsing activity is empty.
Activity recording is turned off.
See more...